Strumento inattivo

Altre lingue WuXi Biologics (Cayman) Inc. Hong Kong S.E.

Azioni

2269

KYG970081090

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

WuXi Biologics Cayman : Named to MSCI ESG Leaders Indexes for Second Consecutive Year	14/06
WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban	13/06
WuXi Biologics Enhances Manufacturing Capability with the Installation of Three 5,000L Single-Use Bioreactors	06/06
WuXi facility boosts bioprocessing capacity with new bioreactors	06/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	31/05
China stocks rise as industrial profits grow; energy, semiconductor shares lead gains	27/05
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3%	17/05
US House committee advances bill to restrict BGI, WuXi AppTec	15/05
US House committee to vote on bill to restrict BGI, WuXi AppTec	15/05
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms	14/05
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	13/05
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties	10/05
Pacific Assets Trust cautiously optimistic after outpacing benchmark	30/04
WuXi Biologics Cayman : Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment	30/04
WuXi Biologics Selected for S&P Global Sustainability Yearbook 2024	16/04
WuXi Biologics Wins 2024 CDMO Leadership Awards in All Categories	03/04
Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	01/04
WuXi Biologics Reports Solid 2023 Annual Results	27/03
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	27/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue WuXi Biologics (Cayman) Inc. Hong Kong S.E.

Azioni

2269

KYG970081090

Altre lingue

Filtri